Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.
Sweeney C, Calingaert B, Holzmann R, Moeller C, Schomakers G, Sok A, Pisa F, Gilsenan A. Physician knowledge of safe use of cyproterone acetate monotherapies and meningioma. Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):300. doi: 10.1002/pds.5687
Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1109-18. doi: 10.1002/pds.4261
Norquist JM, Girman C, Fehnel S, Demuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res. 2012 Aug 1;21(6):1016-20.
Harness J, Mamolo C, DeMuro-Mercon CJ, Fehnel SE, Hill C, Thompson M, Olsen EA, Price VH, Williams VS. The women's hair growth questionnaire: development and validation of a patient-reported measure for treatment efficacy in alopecia. Poster presented at the 2009 American Academy of Dermatology; March 2009.
Seeger JD, West WA, Fernandez C, Rivero E. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. Dermatology. 2006 Dec 1;214(1):32-9.
Lanza L, Rivero Ferrer M, Fernández C, West WA, Seeger JD. Pregnancy incidence among women with inflammatory skin disorders. Poster presented at the 20th International Conference on Pharmacoepidemiology; August 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Aug; 13(Suppl 1):S206-7.